Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS.
Leishmaniasis is emerging as a common and serious opportunistic disease for patients with HIV infection. Almost all cases of HIV-Leishmania coinfection have been described in Mediterranean countries and they occur with various clinical presentations, ranging from typical visceral forms to asymptomatic or atypical cases, including cutaneous and mucocutaneous leishmaniasis. Pentavalent antimony compounds have been the mainstays of antileishmanial therapy for half a century and new lipid formulations of amphotericin B seem reliable, but the most effective treatment remains unknown. We describe a patient who was HIV infected and an intravenous drug user, with an unusual disseminated cutaneous leishmaniasis, after an initial visceral disease and after a 13-month maintenance treatment with liposomal amphotericin. The severe concurrent immunosuppression probably played an essential role in leading to this atypical cutaneous form, characterized by diffuse, nonulcerated, nonscabby maculopapular lesions.
Calza
Leonardo
L
Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Bologna, St Orsola Hospital, via G. Massarenti 11, I-40138 Bologna, Italy. calza@med.unibo.it
D'Antuono
Antonietta
A
Marinacci
Ginevra
G
Manfredi
Roberto
R
Colangeli
Vincenzo
V
Passarini
Beatrice
B
Orioli
Roberto
R
Varoli
Ornella
O
Chiodo
Francesco
F
D017088:AIDS-Related Opportunistic Infections; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D006801:Humans; D016774:Leishmaniasis, Diffuse Cutaneous / Q000188:drug therapy / Q000209:etiology*; D007898:Leishmaniasis, Visceral / Q000150:complications* / Q000188:drug therapy; D008297:Male
D000666:Amphotericin B